Icons / Login Created with Sketch.
Icons / User Created with Sketch.

Exploring the experience of utilization rates of cardioprotective medications in Australian women with a history of cancer.


Modern cancer therapies improve survival rates for many cancers. Cardiovascular disease (CVD) rates and risk factors increase in cancer patients and survivors compared with the general population. CVD emerged as a leading cause of long-term morbidity and mortality in this population [1]. A cross-sectional-observational study of 333 admissions to John Hunter Hospital (JHH) cardiology unit between July 2018-January 2019 identified cardioprotective therapies, especially statins and antiplatelet agents, were underutilized in patients with cancer history compared with patients without cancer and comparable cardiovascular risk factors [2]. This study will explore the experience of use of cardioprotective medications in women with cancer histories compared to those with none on a larger, more representative scale.